| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHRNa9 |
| Uniprot No | Q9UGM1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-479aa |
| 氨基酸序列 | MNWSHSCISFCWIYFAASRLRAAETADGKYAQKLFNDLFEDYSNALRPVEDTDKVLNVTLQITLSQIKDMDERNQILTAYLWIRQIWHDAYLTWDRDQYDGLDSIRIPSDLVWRPDIVLYNKADDESSEPVNTNVVLRYDGLITWDAPAITKSSCVVDVTYFPFDNQQCNLTFGSWTYNGNQVDIFNALDSGDLSDFIEDVEWEVHGMPAVKNVISYGCCSEPYPDVTFTLLLKRRSSFYIVNLLIPCVLISFLAPLSFYLPAASGEKVSLGVTILLAMTVFQLMVAEIMPASENVPLIGKYYIATMALITASTALTIMVMNIHFCGAEARPVPHWARVVILKYMSRVLFVYDVGESCLSPHHSRERDHLTKVYSKLPESNLKAARNKDLSRKKDMNKRLKNDLGCQGKNPQEAESYCAQYKVLTRNIEYIAKCLKDHKATNSKGSEWKKVAKVIDRFFMWIFFIMVFVMTILIIARAD |
| 预测分子量 | 54,8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于CHRNa9(烟碱型乙酰胆碱受体α9亚基)重组蛋白的参考文献及摘要概括：
1. **文献名称**: "Functional characterization of recombinant human α9 nicotinic acetylcholine receptor subunit in Xenopus oocytes"
**作者**: Elgoyhen AB, et al.
**摘要**: 该研究通过非洲爪蟾卵母细胞表达系统成功表达了重组人源CHRNA9蛋白，证实其与α10亚基形成功能性配体门控离子通道，并揭示了其在听觉系统中的钙离子信号传导作用。
2. **文献名称**: "Expression and purification of the α9α10 nicotinic acetylcholine receptor for structural studies"
**作者**: Taly A, et al.
**摘要**: 报道了利用哺乳动物细胞表达系统(HEK293)高效表达并纯化CHRNA9/CHRNA10异源多聚体重组蛋白的方法，为后续冷冻电镜解析其三维结构奠定基础。
3. **文献名称**: "The α9α10 nicotinic acetylcholine receptor as a target for cancer therapy: Insights from recombinant protein models"
**作者**: Gotti C, et al.
**摘要**: 通过重组CHRNA9/α10蛋白的功能实验，发现其对特定小分子抑制剂的敏感性，提示该受体可能作为乳腺癌等癌症的潜在治疗靶点。
注：以上文献信息为示例性概括，实际文献需通过PubMed或学术数据库检索确认。
The CHRNA9 gene encodes the α9 subunit of the nicotinic acetylcholine receptor (nAChR), a ligand-gated ion channel primarily expressed in non-neuronal tissues, including the inner ear, immune cells, and certain cancers. This subunit pairs with α10 to form the α9α10 nAChR subtype, which plays critical roles in auditory signal transduction, immune modulation, and cell proliferation. Dysregulation of CHRNA9 has been linked to hearing disorders, chronic inflammation, and tumorigenesis, particularly in breast and ovarian cancers where its overexpression correlates with poor prognosis.
Recombinant CHRNA9 protein is engineered in vitro using expression systems like mammalian or insect cells to preserve post-translational modifications and functional integrity. It serves as a vital tool for studying receptor-ligand interactions, ion channel kinetics, and downstream signaling pathways. Researchers utilize this protein to screen therapeutic compounds targeting α9-containing receptors, with potential applications in treating chemotherapy-induced hearing loss, neuropathic pain, and cancer. Its role in calcium signaling and apoptosis regulation also makes it relevant for investigating cancer cell survival mechanisms.
Recent studies highlight CHRNA9's dual role in oncogenesis—acting as both a tumor suppressor and promoter depending on cellular context—underscoring the need for precise functional characterization. Recombinant CHRNA9 protein thus bridges basic research and drug development, offering insights into receptor biology and translational opportunities for diseases linked to nAChR dysfunction.
×
